Effects of Cebranopadol on Cocaine-induced Hyperactivity and Cocaine Pharmacokinetics in Rats.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 06 2020
09 06 2020
Historique:
received:
22
01
2020
accepted:
15
05
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
15
1
2021
Statut:
epublish
Résumé
Cebranopadol is known as a highly potent analgesic. Recent studies also demonstrated that administration of cebranopadol significantly decreased cocaine self-administration and significantly reduced cue-induced cocaine-seeking behaviors in rats. However, it was unclear whether these interesting behavioral observations are related to any potential effects of cebranopadol on cocaine pharmacokinetics or cocaine-induced hyperactivity. In principle, a promising therapeutic candidate for cocaine dependence treatment may alter the cocaine pharmacokinetics and/or attenuate cocaine-induced reward and hyperactivity and, thus, decrease cocaine self-administration and reduce cue-induced cocaine-seeking behaviors. In this study, we examined possible effects of cebranopadol on cocaine pharmacokinetics and cocaine-induced hyperactivity for the first time. According to our animal data in rats, cebranopadol did not significantly alter the pharmacokinetics of cocaine. According to our more extensive locomotor activity testing data, cebranopadol itself also dose-dependently induced hyperactivity in rats at doses higher than 50 µg/kg. Cebranopadol at a low dose of 25 µg/kg (p.o.) did not induce significant hyperactivity itself, but significantly potentiated cocaine-induced hyperactivity on Days 4 to 7 after the repeated daily dosing of the drug.
Identifiants
pubmed: 32518276
doi: 10.1038/s41598-020-66250-z
pii: 10.1038/s41598-020-66250-z
pmc: PMC7283222
doi:
Substances chimiques
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine
0
Analgesics
0
Indoles
0
Spiro Compounds
0
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
9254Subventions
Organisme : NIDA NIH HHS
ID : R01 DA035552
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA032910
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA013930
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA025100
Pays : United States
Références
Tzschentke, T. M., Linz, K., Koch, T. & Christoph, T. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors. Handb. Exp. Pharmacol. 254, 367–398, https://doi.org/10.1007/164_2019_206 (2019).
doi: 10.1007/164_2019_206
pubmed: 30927089
Linz, K. et al. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. The Journal of pharmacology and experimental therapeutics 349, 535–548, https://doi.org/10.1124/jpet.114.213694 (2014).
doi: 10.1124/jpet.114.213694
pubmed: 24713140
Gohler, K. et al. Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study. J Clin Psychopharmacol 39, 46–56, https://doi.org/10.1097/jcp.0000000000000995 (2019).
doi: 10.1097/jcp.0000000000000995
pubmed: 30531478
Eerdekens, M. H. et al. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. European journal of pain (London, England) 23, 577–588, https://doi.org/10.1002/ejp.1331 (2019).
doi: 10.1002/ejp.1331
Tzschentke, T. M., Kogel, B. Y., Frosch, S. & Linz, K. Limited potential of cebranopadol to produce opioid-type physical dependence in rodents. Addict. Biol. 23, 1010–1019, https://doi.org/10.1111/adb.12550 (2018).
doi: 10.1111/adb.12550
pubmed: 28944554
Ruzza, C., Holanda, V. A., Gavioli, E. C., Trapella, C. & Calo, G. NOP agonist action of cebranopadol counteracts its liability to promote physical dependence. Peptides 112, 101–105, https://doi.org/10.1016/j.peptides.2018.12.001 (2019).
doi: 10.1016/j.peptides.2018.12.001
pubmed: 30550769
Zhao, R. J. et al. Orphanin FQ/nociceptin blocks methamphetamine place preference in rats. Neuroreport 14, 2383–2385, https://doi.org/10.1097/01.wnr.0000095707.83808.2c (2003).
doi: 10.1097/01.wnr.0000095707.83808.2c
pubmed: 14663196
Sakoori, K. & Murphy, N. P. Endogenous nociceptin (orphanin FQ) suppresses basal hedonic state and acute reward responses to methamphetamine and ethanol, but facilitates chronic responses. Neuropsychopharmacology 33, 877–891, https://doi.org/10.1038/sj.npp.1301459 (2008).
doi: 10.1038/sj.npp.1301459
pubmed: 17522627
Ciccocioppo, R. et al. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl) 172, 170–178, https://doi.org/10.1007/s00213-003-1645-1 (2004).
doi: 10.1007/s00213-003-1645-1
Bird, M. F. & Lambert, D. G. Simultaneous targeting of multiple opioid receptor types. Current opinion in supportive and palliative care 9, 98–102, https://doi.org/10.1097/spc.0000000000000129 (2015).
doi: 10.1097/spc.0000000000000129
pubmed: 25872121
Azzam, A. A. H., McDonald, J. & Lambert, D. G. Hot topics in opioid pharmacology: mixed and biased opioids. British journal of anaesthesia 122, e136–e145, https://doi.org/10.1016/j.bja.2019.03.006 (2019).
doi: 10.1016/j.bja.2019.03.006
pubmed: 31010646
Dietis, N. et al. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. British journal of anaesthesia 103, 38–49, https://doi.org/10.1093/bja/aep129 (2009).
doi: 10.1093/bja/aep129
pubmed: 19474215
Shen, Q., Deng, Y., Ciccocioppo, R. & Cannella, N. Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors. Frontiers in psychiatry 8, 234, https://doi.org/10.3389/fpsyt.2017.00234 (2017).
doi: 10.3389/fpsyt.2017.00234
pubmed: 29180970
pmcid: 5693905
de Guglielmo, G. et al. Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats. The Journal of pharmacology and experimental therapeutics 362, 378–384, https://doi.org/10.1124/jpet.117.241042 (2017).
doi: 10.1124/jpet.117.241042
pubmed: 28645915
pmcid: 5539589
Zheng, F. & Zhan, C.-G. in Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes (ed Ivan D. Montoya) 187-225 (Springer (2016).
Zheng, F. et al. A highly efficient cocaine-detoxifying enzyme obtained by computational design. Nature Commun. 5, 3457. 3410.1388/ncomms4457 (2014).
Smith, M. A., Greene-Naples, J. L., Lyle, M. A., Iordanou, J. C. & Felder, J. N. The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors. The Journal of pharmacology and experimental therapeutics 330, 468–475, https://doi.org/10.1124/jpet.108.150011 (2009).
doi: 10.1124/jpet.108.150011
pubmed: 19403853
pmcid: 2713083
Kalivas, P. W. & Duffy, P. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. The. Journal of neuroscience: the official journal of the Society for Neuroscience 13, 266–275 (1993).
doi: 10.1523/JNEUROSCI.13-01-00266.1993
Thomas, M. J., Kalivas, P. W. & Shaham, Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. British journal of pharmacology 154, 327–342, https://doi.org/10.1038/bjp.2008.77 (2008).
doi: 10.1038/bjp.2008.77
pubmed: 18345022
pmcid: 2442442
Beninger, R. J. The role of dopamine in locomotor activity and learning. Brain research 287, 173–196, https://doi.org/10.1016/0165-0173(83)90038-3 (1983).
doi: 10.1016/0165-0173(83)90038-3
pubmed: 6357357
Kalivas, P. W. & Stewart, J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain research. Brain research reviews 16, 223–244 (1991).
doi: 10.1016/0165-0173(91)90007-U
Sharples, S. A., Koblinger, K., Humphreys, J. M. & Whelan, P. J. Dopamine: a parallel pathway for the modulation of spinal locomotor networks. Frontiers in neural circuits 8, 55, https://doi.org/10.3389/fncir.2014.00055 (2014).
doi: 10.3389/fncir.2014.00055
pubmed: 24982614
pmcid: 4059167
Mogenson, G. J., Jones, D. L. & Yim, C. Y. From motivation to action: functional interface between the limbic system and the motor system. Progress in neurobiology 14, 69–97 (1980).
doi: 10.1016/0301-0082(80)90018-0
Schunk, S. et al. Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol. ACS medicinal chemistry letters 5, 857–862, https://doi.org/10.1021/ml500117c (2014).
doi: 10.1021/ml500117c
pubmed: 25147603
pmcid: 4137374
Rizzi, A. et al. Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist. Pharmacology research & perspectives 4, e00247, https://doi.org/10.1002/prp2.247 (2016).
doi: 10.1002/prp2.247
Schuelke, G. S., Konkol, R. J., Terry, L. C. & Madden, J. A. Effect of cocaine metabolites on behavior: possible neuroendocrine mechanisms. Brain research bulletin 39, 43–48, https://doi.org/10.1016/0361-9230(95)02040-3 (1996).
doi: 10.1016/0361-9230(95)02040-3
pubmed: 8846107
Lau, C. E., Falk, J. L. & King, G. R. Oral cocaine self-administration: relation of locomotor activity to pharmacokinetics. Pharmacology, biochemistry, and behavior 43, 45–51, https://doi.org/10.1016/0091-3057(92)90637-u (1992).
doi: 10.1016/0091-3057(92)90637-u
pubmed: 1409818
Falk, J. L., Ma, F. & Lau, C. E. Chronic oral cocaine self-administration: pharmacokinetics and effects on spontaneous and discriminative motor functions. The Journal of pharmacology and experimental therapeutics 257, 457–465 (1991).
pubmed: 2020003
Tzschentke, T. M. & Rutten, K. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat. Neuropharmacology 129, 100–108, https://doi.org/10.1016/j.neuropharm.2017.11.026 (2018).
doi: 10.1016/j.neuropharm.2017.11.026
pubmed: 29155273
Andersen, J. M., Ripel, A., Boix, F., Normann, P. T. & Morland, J. Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo. The Journal of pharmacology and experimental therapeutics 331, 153–161, https://doi.org/10.1124/jpet.109.152462 (2009).
doi: 10.1124/jpet.109.152462
pubmed: 19541908
Marquez, P., Baliram, R., Kieffer, B. L. & Lutfy, K. The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference. Neuropharmacology 52, 1336–1341, https://doi.org/10.1016/j.neuropharm.2007.01.005 (2007).
doi: 10.1016/j.neuropharm.2007.01.005
pubmed: 17367825
pmcid: 2267901
Yeh, S. Y. & Haertzen, C. A. Cocaine-induced locomotor activity in rats. Pharmacology, biochemistry, and behavior 39, 723–727, https://doi.org/10.1016/0091-3057(91)90154-t (1991).
doi: 10.1016/0091-3057(91)90154-t
pubmed: 1784601
Cailhol, S. & Mormede, P. Strain and sex differences in the locomotor response and behavioral sensitization to cocaine in hyperactive rats. Brain research 842, 200–205, https://doi.org/10.1016/s0006-8993(99)01742-4 (1999).
doi: 10.1016/s0006-8993(99)01742-4
pubmed: 10526110
Johnson, S. W. & North, R. A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. The Journal of neuroscience: the official journal of the Society for Neuroscience 12, 483–488 (1992).
doi: 10.1523/JNEUROSCI.12-02-00483.1992
Kuhar, M. J., Ritz, M. C. & Boja, J. W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends in neurosciences 14, 299–302 (1991).
doi: 10.1016/0166-2236(91)90141-G
Wise, R. A. & Bozarth, M. A. A psychomotor stimulant theory of addiction. Psychological review 94, 469–492 (1987).
doi: 10.1037/0033-295X.94.4.469
Smith, M. A. et al. The effects of repeated opioid administration on locomotor activity: II. Unidirectional cross-sensitization to cocaine. The Journal of pharmacology and experimental therapeutics 330, 476–486, https://doi.org/10.1124/jpet.108.150037 (2009).
doi: 10.1124/jpet.108.150037
pubmed: 19403852
pmcid: 2713084
Placenza, F. M., Rajabi, H. & Stewart, J. Effects of chronic buprenorphine treatment on levels of nucleus accumbens glutamate and on the expression of cocaine-induced behavioral sensitization in rats. Psychopharmacology 200, 347–355 (2008).
doi: 10.1007/s00213-008-1210-z
Zheng, F. et al. Most efficient cocaine hydrolase designed by virtual screening of transition states. Journal of the American Chemical Society 130, 12148-12155, https://doi.org/10.1021/ja803646t (2008).
Zheng, F. & Zhan, C. G. Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose? Future medicinal chemistry 4, 125–128, https://doi.org/10.4155/fmc.11.171 (2012).
Zheng, F. & Zhan, C.-G. Enzyme therapy approaches for treatment of drug overdose and addiction. Future Med. Chem. 3, 9–13 (2011).
doi: 10.4155/fmc.10.275
Yao, J., Chen, X., Zheng, F. & Zhan, C.-G. Catalytic reaction mechanism for drug metabolism in human carboxylesterase-1: Cocaine hydrolysis pathway. Mol. Pharmaceutics 15, 3871–3880 (2018).
doi: 10.1021/acs.molpharmaceut.8b00354
Zhan, C.-G., Zheng, F. & Landry, D. W. Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J. Am. Chem. Soc. 125, 2462–2474 (2003).
doi: 10.1021/ja020850+
Pan, Y. et al. Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc. Natl Acad. Sci. USA 102, 16656–16661, https://doi.org/10.1073/pnas.0507332102 (2005).
doi: 10.1073/pnas.0507332102
pubmed: 16275916
Zhan, M., Hou, S., Zhan, C.-G. & Zheng, F. Kinetic characterization of high-activity mutants of human butyrylcholinesterase for the cocaine metabolite norcocaine. Biochem. J. 457, 197–206 (2014).
doi: 10.1042/BJ20131100
Hou, S., Zhan, M., Zheng, X., Zhan, C.-G. & Zheng, F. Kinetic characterization of human butyrylcholinesterase mutants for hydrolysis of cocaethylene. Biochem. J. 460, 447–457 (2014).
doi: 10.1042/BJ20140360
Chen, X. et al. Metabolic enzymes of cocaine metabolite benzoylecgonine. ACS Chem. Biol. 11, 2186–2194 (2016).
doi: 10.1021/acschembio.6b00277
Madden, J. A. & Powers, R. H. Effect of cocaine and cocaine metabolites on cerebral arteries in vitro. Life Sci 47, 1109–1114, https://doi.org/10.1016/0024-3205(90)90169-r (1990).
doi: 10.1016/0024-3205(90)90169-r
pubmed: 2233129
Morishima, H. O., Whittington, R. A., Iso, A. & Cooper, T. B. The comparative toxicity of cocaine and its metabolites in conscious rats. Anesthesiology 90, 1684–1690, https://doi.org/10.1097/00000542-199906000-00025 (1999).
doi: 10.1097/00000542-199906000-00025
pubmed: 10360867
Goldstein, R. A., DesLauriers, C., Burda, A. & Johnson-Arbor, K. Cocaine: history, social implications, and toxicity: a review. Seminars in diagnostic pathology 26, 10–17 (2009).
doi: 10.1053/j.semdp.2008.12.001
Zheng, X., Shang, L., Zhan, C.-G. & Zheng, F. In vivo characterization of toxicity of norcocaethylene and norcocaine identified as the most toxic cocaine metabolites in male mice. Drug Alcohol Depend. 204, 107410.101016/j.drugalcdep.102019.107404.107033, https://doi.org/10.1016/j.drugalcdep.2019.04.033 (2019).
Chen, X. et al. A quantitative LC-MS/MS method for simultaneous determination of cocaine and its metabolites in whole blood. J. Pharm. Biomed. Anal. 134, 243–251, https://doi.org/10.1016/j.jpba.2016.11.024 (2017).
doi: 10.1016/j.jpba.2016.11.024
pubmed: 27923200
Zheng, X. et al. Catalytic activities of cocaine hydrolases against the most toxic cocaine metabolite norcocaethylene. Org. Biomol. Chem. 18, 1968–1977 (2020).
doi: 10.1039/C9OB02762A
Benuck, M., Lajtha, A. & Reith, M. E. Pharmacokinetics of systemically administered cocaine and locomotor stimulation in mice. The Journal of pharmacology and experimental therapeutics 243, 144–149 (1987).
pubmed: 3668848
Spiehler, V. R. & Reed, D. Brain concentrations of cocaine and benzoylecgonine in fatal cases. Journal of forensic sciences 30, 1003–1011 (1985).
pubmed: 4067533
Chen, X. et al. Long-acting cocaine hydrolase for addiction therapy. Proc. Natl Acad. Sci. USA 113, 422–427 (2016).
doi: 10.1073/pnas.1517713113
Zheng, X. et al. Effectiveness of a cocaine hydrolase for cocaine toxicity treatment in male and female rats. AAPS J. 20, 3, https://doi.org/10.1208/s12248-12017-10167-12244 (2018).
doi: 10.1208/s12248-12017-10167-12244
Zhang, T. et al. Clinical potential of an enzyme-based novel therapy for cocaine overdose. Sci. Rep. 7, 15303 (2017).
doi: 10.1038/s41598-017-14105-5